Some vaccines, like the front-runner from Pfizer Inc. and BioNTech SE, must be kept at ultra-cold temperatures and require complex handling to remain viable. That storage requirement is an obstacle that will need to be tackled before the vaccine can be made broadly available, according to experts, and the deployment costs raise worries that poorer nations will be left behind.
CureVac said its stability study is ongoing, aimed at further evaluating the potential for a longer commercial shelf-life.
Speaking at an event Thursday, Anthony Fauci, the top U.S. infectious disease official, pointed to the next vaccines in the pipeline that won’t have the need to be stored at such cold temperatures.
